ACH-TELMISARTAN TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

TELMISARTAN

から入手可能:

ACCORD HEALTHCARE INC

ATCコード:

C09CA07

INN（国際名）:

TELMISARTAN

投薬量:

80MG

医薬品形態:

TABLET

構図:

TELMISARTAN 80MG

投与経路:

ORAL

パッケージ内のユニット:

15G/50G

処方タイプ:

Prescription

治療領域:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

製品概要:

Active ingredient group (AIG) number: 0138223002; AHFS:

認証ステータス:

APPROVED

承認日:

2021-03-05

製品の特徴

ACH-Telmisartan - Product Monograph
_ _
_ _
_ _
_ _
_ _
_ _
Page 1 of 35
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ACH-TELMISARTAN
Telmisartan Tablets
Tablet, 40 mg and 80 mg, Oral
Manufacturer’s Standard
Angiotensin II AT
1
Receptor Blocker
Accord Healthcare Inc.
3535 boul. St. Charles, Suite 704
Kirkland, QC, H9H 5B9
Canada
Date of Initial Authorization:
June 7, 2013
Date of Revision:
June 26, 2023
SUBMISSION CONTROL NUMBER: 271374
ACH-Telmisartan - Product Monograph
_ _
_ _
_ _
_ _
_ _
_ _
Page 2 of 35
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
06/2023
7 WARNINGS AND PRECAUTIONS
06/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL
INFORMATION.......................................................................
4
1
INDICATIONS
..................................................................................................................
4
1.1
Pediatrics
...............................................................................................................
4
1.2
Geriatrics
...............................................................................................................
4
2
CONTRAINDICATIONS.....................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
................................................................ 5
4
DOSAGE AND ADMINISTRATION
....................................................................................
5
4.1
Dosing Considerations
............................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.................................................